Stocktoria
Inmune Bio, Inc. INMB
Inmune Bio, Inc. (INMB) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $50,000 at a -91866.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| INMB | Inmune Bio, Inc. | 3/9 | — | — | — |
| ENTX | Entera Bio Ltd. | 2/9 | — | — | — |
| SNTI | Senti Biosciences Holdings, Inc. | 2/9 | — | — | — |
| CELZ | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | 4/9 | -1.04 | — | — |
| SRRK | Scholar Rock Holding Corp | 1/9 | -9.91 | — | -100% |
| SABS | SAB Biotherapeutics, Inc. | 3/9 | 6.9 | 21.9 | — |
| RVMD | Revolution Medicines, Inc. | 1/9 | -0.01 | — | — |
About Inmune Bio, Inc.
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
FAQ
Is INMB financially healthy?
Inmune Bio, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does INMB pay a dividend?
No, Inmune Bio, Inc. does not currently pay a dividend.
How profitable is INMB?
In FY2025, Inmune Bio, Inc. had a net margin of -91866.0% and a return on equity of -195.3%.
What is the analyst price target for INMB?
The average Wall-Street price target for Inmune Bio, Inc. is $7.00, about 243.1% above the recent price, from 4 analysts (consensus: strong buy).
Is INMB a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Inmune Bio, Inc.: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.